Novartis CEO Vas Narasimhan named to Anthropic board
This image was generated by AI and may not depict real events.
Novartis CEO Vas Narasimhan has been appointed to Anthropic's board of directors, bringing his experience in the highly regulated life sciences sector to the AI firm. Narasimhan's addition gives Trust-appointed directors a majority on the board, ensuring Anthropic's mission prioritizes safety and public benefit.
Anthropic, a multi-billion-dollar AI firm, has appointed Novartis CEO Vas Narasimhan to its board of directors. This move solidifies the company's governance and ensures its 'constitutional AI' mission remains intact as it scales. Narasimhan brings experience from the highly regulated life sciences sector, having overseen the approval of over 35 novel medicines at Novartis. His presence on the board, alongside tech luminaries like Mike Krieger and Reed Hastings, suggests Anthropic is applying rigorous safety standards to AI model releases. Anthropic aims to bridge the gap between Silicon Valley's 'move fast' culture and the 'do no harm' ethics of modern medicine. With Narasimhan's guidance, the company will prioritize safety and public benefit as it continues to develop AI models like Claude.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.